The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Cabrero, M
- Valcarcel, D
- Rovira, M
- Garcia-Marco, JA
- Loscertales, J
- Moreno, C
- Duarte, R
- Terol, MJ
- Villamor, N
- Abrisqueta, P
- Caballero, D
- Delgado, J
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0268-3369, 1476-5365
- Tipo:
- Letter
- Páginas:
- 1404-1407
- DOI:
- 10.1038/bmt.2016.145
- PubMed:
- 27214073
- Factor de Impacto:
- 1,986 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BONE MARROW TRANSPLANTATION SPRINGERNATURE
Citas Recibidas en Web of Science: 4
Documentos
- No hay documentos
Filiaciones
Cita
Montesinos P,Cabrero M,Valcarcel D,Rovira M,Garcia JA,Loscertales J,Moreno C,Duarte R,Terol MJ,Villamor N,Abrisqueta P,Caballero D,Sanz J,Delgado J. The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). Bone Marrow Transplant. 2016. 51(10):p. 1404-1407. IF:3,874. (2).
Portal de investigación